Zimmer Biomet Holdings financials
$91.62+0.64%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B | $6.13B | $7.98B | $7.93B | $7.80B | $7.67B |
| Gross profit | $5.74B | $5.49B | $5.31B | $4.92B | $4.87B | $4.30B | $5.73B | $5.66B | $5.67B | $5.29B |
| Gross margin | 69.7% | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% | 71.8% | 71.4% | 72.7% | 68.9% |
| Operating income | $1.10B | $1.29B | $1.28B | $696.3M | $860.3M | $94.5M | $1.15B | $33.8M | $799.3M | $821.1M |
| Net income | $705.1M | $903.8M | $1.02B | $231.4M | $401.6M | -$138.9M | $1.13B | -$379.2M | $1.81B | $305.9M |
| Net margin | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% | −2.3% | 14.2% | −4.8% | 23.2% | 4.0% |
| Diluted EPS | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 |
| EBITDA | $2.37B | $2.50B | $2.38B | $2.12B | $1.94B | $1.60B | $2.28B | $2.09B | $2.21B | $1.89B |
| Operating cash flow | $1.70B | $1.50B | $1.58B | $1.28B | $1.50B | $1.20B | $1.59B | $1.75B | $1.58B | $1.63B |
| Free cash flow | $1.17B | $1.06B | $978.8M | $838.5M | $1.08B | $833.6M | $1.06B | $1.31B | $1.09B | $1.10B |
| Diluted shares | 198.7M | 203.9M | 209.7M | 210.3M | 210.4M | 207.0M | 206.7M | 203.5M | 203.7M | 202.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $591.9M | $525.5M | $415.8M | $375.7M | $378.1M | $802.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $7.52B | $6.20B | $5.77B | $5.70B | $7.07B | $8.13B |
| Total assets | $23.09B | $21.37B | $21.50B | $21.07B | $23.46B | $24.42B |
| Total liabilities | $10.39B | $8.89B | $9.01B | $9.04B | $10.79B | $12.22B |
| Shareholders' equity | $12.71B | $12.48B | $12.49B | $12.03B | $12.67B | $12.20B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology